Clinical Trial Update: Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003) [Phase 1]

View source ↗

Summary

Phase 1 trial update for acute dosing of MK-8892 in participants with pulmonary arterial hypertension (PAH) has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• MK-8892 (MK-8892)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pulmonary Arterial Hypertension | Phase 1 | Status: TERMINATED | Results posted: 2018-10-22